MedTrace Logo

Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells

NCT00562666 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2012-06-22

No results posted yet for this study

Summary

For most patients with hepatocellular carcinoma, surgery or other curative procedures are not possible and only palliative measures could be applied (chemoembolization, targeted drugs, best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product will be evaluated in patients in a palliative setting. All patients will have one hepatic intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be evaluated for safety.

Conditions

Interventions

OTHER

T gamma delta lymphocytes

Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes

Sponsors & Collaborators

  • Innate Pharma

    collaborator INDUSTRY

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Jean-Luc RAOUL, MD, PhD · CRLCC Eugène Marquis, Rennes

  • Eric BELLISSANT, MD, PhD · Rennes University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562666 on ClinicalTrials.gov